{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:43:25Z","timestamp":1791085405809,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1124\/mol.113.088005","type":"journal-article","created":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T04:46:15Z","timestamp":1374554775000},"page":"562-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Sorafenib\/Regorafenib and Phosphatidyl Inositol 3 Kinase\/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells"],"prefix":"10.1016","volume":"84","author":[{"given":"Gangadharan B.","family":"Sajithlal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein A.","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Cruickshanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedmehrad","family":"Tavallai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahangir","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Poklepovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/mol.113.088005_bib1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1128\/MCB.06159-11","article-title":"Role of AMPK-mTOR-Ulk1\/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks","volume":"32","author":"Alers","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1124\/mol.113.088005_bib2","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1158\/0008-5472.CAN-11-0898","article-title":"Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells","volume":"71","author":"Bareford","year":"2011","journal-title":"Cancer Res"},{"key":"10.1124\/mol.113.088005_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.257.4.2","article-title":"Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival","volume":"4","author":"Car\u00f3n","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/mol.113.088005_bib4","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/jcp.24148","article-title":"Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery","volume":"228","author":"Carr","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1124\/mol.113.088005_bib5","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1002\/cncr.27668","article-title":"Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy","volume":"118","author":"Cho","year":"2012","journal-title":"Cancer"},{"key":"10.1124\/mol.113.088005_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1124\/mol.112.081539","article-title":"Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress","volume":"82","author":"Cruickshanks","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.113.088005_bib7","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2006.10.2871","article-title":"Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma","volume":"25","author":"Elser","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1124\/mol.113.088005_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.mito.2012.05.001","article-title":"Modulation of mitochondrial apoptosis by PI3K inhibitors","volume":"13","author":"Fulda","year":"2013","journal-title":"Mitochondrion"},{"key":"10.1124\/mol.113.088005_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.seminoncol.2006.04.002","article-title":"Role of Raf kinase in cancer: therapeutic potential of targeting the Raf\/MEK\/ERK signal transduction pathway","volume":"33","author":"Gollob","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1124\/mol.113.088005_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1101\/gad.186189.111","article-title":"Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors","volume":"26","author":"Gores","year":"2012","journal-title":"Genes Dev"},{"key":"10.1124\/mol.113.088005_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/ijc.25394","article-title":"Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma","volume":"128","author":"Gwak","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1124\/mol.113.088005_bib12","first-page":"639","article-title":"Gene alterations in the PI3K\/PTEN\/AKT pathway as a mechanism of drug-resistance (review)","volume":"40","author":"Hafsi","year":"2012","journal-title":"Int J Oncol"},{"key":"10.1124\/mol.113.088005_bib13","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-12-0714","article-title":"A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors","volume":"18","author":"Hong","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.113.088005_bib14","first-page":"1303","article-title":"Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review)","volume":"27","author":"Ibrahim","year":"2012","journal-title":"Oncol Rep"},{"key":"10.1124\/mol.113.088005_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/0008-5472.CAN-07-6656","article-title":"Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance","volume":"69","author":"Ihle","year":"2009","journal-title":"Cancer Res"},{"key":"10.1124\/mol.113.088005_bib16","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1158\/0008-5472.CAN-07-6278","article-title":"Mcl-1: a gateway to TRAIL sensitization","volume":"68","author":"Kim","year":"2008","journal-title":"Cancer Res"},{"key":"10.1124\/mol.113.088005_bib17","doi-asserted-by":"crossref","unstructured":"Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C (2013) Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD\/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia [Epub ahead of print].","DOI":"10.1038\/leu.2013.28"},{"key":"10.1124\/mol.113.088005_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00795-011-0558-z","article-title":"Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled","volume":"44","author":"Matsuda","year":"2011","journal-title":"Med Mol Morphol"},{"key":"10.1124\/mol.113.088005_bib19","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.4161\/cbt.7.10.6623","article-title":"Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation","volume":"7","author":"Park","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1124\/mol.113.088005_bib20","doi-asserted-by":"crossref","first-page":"35217","DOI":"10.1074\/jbc.M506551200","article-title":"Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation","volume":"280","author":"Rahmani","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088005_bib21","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1128\/MCB.01080-06","article-title":"The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress","volume":"27","author":"Rahmani","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1124\/mol.113.088005_bib22","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1182\/blood-2008-09-177881","article-title":"The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K\/Akt and MEK\/ERK1\/2 pathways","volume":"114","author":"Rahmani","year":"2009","journal-title":"Blood"},{"key":"10.1124\/mol.113.088005_bib23","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1158\/0008-5472.CAN-12-1365","article-title":"Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism","volume":"73","author":"Rahmani","year":"2013","journal-title":"Cancer Res"},{"key":"10.1124\/mol.113.088005_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/mol.113.088005_bib25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1476-4598-10-90","article-title":"Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K\/mTOR inhibitor, in combination with sorafenib","volume":"10","author":"Roulin","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1124\/mol.113.088005_bib26","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4161\/cc.8.6.7906","article-title":"Tyrosine phosphorylation and CD95: a FAScinating switch","volume":"8","author":"Sancho-Martinez","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1124\/mol.113.088005_bib27","doi-asserted-by":"crossref","first-page":"22128","DOI":"10.1074\/jbc.M800271200","article-title":"Oncogenic B-RafV600E inhibits apoptosis and promotes ERK-dependent inactivation of Bad and Bim","volume":"283","author":"Sheridan","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1124\/mol.113.088005_bib28","doi-asserted-by":"crossref","unstructured":"Sun H, Wang Z, Yakisich JS. (2012) Natural products targeting autophagy via the PI3K\/Akt\/mTOR pathway as anticancer agents. Anticancer Agents Med Chem [Epub ahead of print].","DOI":"10.2174\/18715206113139990130"},{"key":"10.1124\/mol.113.088005_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/mol.109.061820","article-title":"Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7\/interleukin-24-induced killing in ovarian carcinoma cells","volume":"77","author":"Yacoub","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1124\/mol.113.088005_bib30","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1158\/1078-0432.CCR-08-0469","article-title":"Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24037970?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24037970?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.113.088005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T11:16:28Z","timestamp":1739963788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24037970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0026895X24037970"],"URL":"https:\/\/doi.org\/10.1124\/mol.113.088005","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib\/Regorafenib and Phosphatidyl Inositol 3 Kinase\/Thymoma Viral Proto-Oncogene Inhibition Interact to Kill Tumor Cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.113.088005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2013 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}